Friday, October 02, 2009
Biocon insulin pill
The world's first oral insulin pills will hit the markets in 2011, after human clinical trials reached their final stages, says Biocon Managing Director Kiran Mazumdar-Shaw. "This is a product that we see to be a game-changer," Mazumdar-Shaw, 53, said. "It has huge potential and certainly can be a multibillion dollar blockbuster."
Bloomberg
Of the estimated 246 million people affected by diabetes worldwide, about 5 percent to 10 percent have the type 1 form that’s marked by the inability to produce insulin, a hormone that turns blood sugar into energy, according to the International Diabetes Federation. India is the worst-affected by diabetes, with about 41 million sufferers, followed by China and the U.S.
Biocon has also purchased IDL Speciality Chemicals, which makes Active Pharmaceuticals Ingredients (API), the basic raw material used in the manufacturing of medicines. Biocon has bought IDL from Gulf Oil Corporation, a Hinduja Group company.
Bloomberg
Of the estimated 246 million people affected by diabetes worldwide, about 5 percent to 10 percent have the type 1 form that’s marked by the inability to produce insulin, a hormone that turns blood sugar into energy, according to the International Diabetes Federation. India is the worst-affected by diabetes, with about 41 million sufferers, followed by China and the U.S.
Biocon has also purchased IDL Speciality Chemicals, which makes Active Pharmaceuticals Ingredients (API), the basic raw material used in the manufacturing of medicines. Biocon has bought IDL from Gulf Oil Corporation, a Hinduja Group company.
